Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för Tozadenant. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

7 träffar

Bibliografisk träff 2022-04-18

Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.

Zhong Z, He X, Ge J, Zhu J, Yao C, Cai H, Ye XY, Xie T, Bai R.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114378

Bibliografisk träff 2021-10-13

Adenosine receptor antagonists: Recent advances and therapeutic perspective.

Saini A, Patel R, Gaba S, Singh G, Gupta GD, Monga V.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113907

Bibliografisk träff 2021-01-30

Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands.

Renk DR, Skraban M, Bier D, Schulze A, Wabbals E, Wedekind F, Neumaier F, Neumaier B, Holschbach M.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2021.113214

Bibliografisk träff 2020-07-30

Adenosine A2A Receptor Antagonists for Cancer Immunotherapy.

Yu F, Zhu C, Xie Q, Wang Y.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c00237

Bibliografisk träff 2019-11-15

Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonists.

Abdelrahman A, Yerande SG, Namasivayam V, Klapschinski TA, Alnouri MW, El-Tayeb A, Müller CE.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.111879

Bibliografisk träff 2017-01-17

Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation.

Basu S, Barawkar DA, Thorat S, Shejul YD, Patel M, Naykodi M, Jain V, Salve Y, Prasad V, Chaudhary S, Ghosh I, Bhat G, Quraishi A, Patil H, Ansari S, Menon S, Unadkat V, Thakare R, Seervi MS, Meru AV, De S, Bhamidipati RK, Rouduri SR, Palle VP, Chug A, Mookhtiar KA.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.6b01584

Bibliografisk träff 2013-11-15

Adenosine A2A receptor as a drug discovery target.

de Lera Ruiz M, Lim YH, Zheng J.

J Med Chem · review; journal article · DOI 10.1021/jm4011669

Gå till forskningen.

Publikationer i urvalet

Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.

Adenosine receptor antagonists: Recent advances and therapeutic perspective.

Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A<sub>2A</sub> receptor ligands.

Adenosine A<sub>2A</sub> Receptor Antagonists for Cancer Immunotherapy.

Substituted 4-phenylthiazoles: Development of potent and selective A<sub>1</sub>, A<sub>3</sub> and dual A<sub>1</sub>/A<sub>3</sub> adenosine receptor antagonists.

Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A<sub>2A</sub> Receptor Antagonists and Their Biological Evaluation.

Adenosine A2A receptor as a drug discovery target.